On Wednesday, Ionis Pharmaceuticals Inc. (NASDAQ:IONS) said it is cutting the annual list price of its triglyceride-lowering drug Tryngolza (olezarsen) to $40,000 from $595,000. The move positions the therapy more competitively ahead of a potential label expansion into severe hypertriglyceridemia (sHTG) later this year.

Hypertriglyceridemia is a condition characterized by abnormally high levels of triglycerides (fats) in the blood.

The revised wholesale acquisition cost (WAC) will take effect on April 1.

The drug is currently approved for familial chylomicronemia syndrome (FCS), but the pricing reset comes as Ionis prepares for a broader launch, with an FDA decision in sHTG expected by June 30.

FCS is a rare, inherited metabolic disorder caused by lipoprotein lipase (LPL) enzyme deficiency, leading to extremely high triglyceride levels.

Pricing Reset Ahead Of Larger Market Opportunity

Ionis had previously guided to a significantly lower WAC range of $10,000 to $20,000 annually for sHTG.

However, William Blair notes that the earlier-than-expected pricing adjustment reflects alignment with payer contracting cycles, as April 1 marks a key benchmark for commercial insurance budgeting.

The timing suggests Ionis is proactively positioning Tryngolza for formulary inclusion ahead of a potentially larger patient population.

Analysts See Strategic Upside In Revised Pricing

Analyst Myles Minter described the pricing revision as a positive development as Ionis approaches a potential sHTG launch.

At $40,000 annually, the new price point is higher than prior guidance but aligns more closely with expectations based on clinical outcomes. Analysts note that Tryngolza's demonstrated impact on pancreatitis risk in the CORE studies supports a premium relative to earlier projections.

The updated pricing also places the drug below the $60,000 WAC of Arrowhead Pharmaceuticals Inc.'s (NASDAQ:ARWR) therapy, plozasiran, marketed as Redemplo, while offering validated outcomes data.

Revenue Outlook Under Review

The pricing shift has prompted analysts to revisit their financial models.

Prior assumptions were based on a net annual price of roughly $20,400, and updated forecasts are expected following Ionis' first-quarter earnings report, when management may provide product-specific guidance.

The revised pricing could drive upside to existing peak sales estimates. Previous projections exceeded $2 billion in sHTG, with some models reaching $2.6 billion based on 20% U.S. market penetration under the earlier pricing framework.

Ionis Pharmaceuticals Approval Catalyst Could Unlock Blockbuster Potential

Analysts remain optimistic about regulatory approval by the June 30 PDUFA date. If approved, Tryngolza would enter a significantly larger market, transforming it into a wholly owned commercial opportunity for Ionis.

The combination of competitive pricing, strong clinical data, and broader indication potential positions the drug as a key near-term growth driver.

William Blair maintains the Outperform rating on Ionis.

IONS Stock Price Activity: Ionis Pharmaceuticals shares were up 3.74% at $75.42 at the time of publication on Thursday, according to Benzinga Pro data.

Image via Shutterstock